Category: Biotech

BioStem Technologies (OTC: BSEM) has received Investigational Review Board (IRB) approval for a clinical studythat will investigate the utilization and effects of its VendajeⓇ wound… [Read More]

Bionomics Limited’s (Nasdaq: BNOX) Phase 2b study evaluating BNC210 in post-traumatic stress disorder (PTSD) has garnered positive topline results, sending the company’s share price soaring… [Read More]

Clene (Nasdaq: CLNN) has shared long-term follow-up data for patients treated with CNM-Au8 30mg for up to 133 weeks in the HEALEY ALS Platform Trial…. [Read More]

Vaccines and immunotherapies company, GeoVax Labs, Inc., (Nasdaq: GOVX) will enhance its manufacturing capabilities following the signing of a landmark commercial license agreement with ProBioGen…. [Read More]

Lexaria Bioscience Corp. (Nasdaq:LEXX) will expand its established diabetes study program, launching new human and animal studies to evaluate DehydraTECH™-processed glucagon-like peptide-1 (GLP-1) drugs, such… [Read More]

Soleno Therapeutics (Nasdaq: SLNO) shares skyrocketed more than 500% after the company announced positive topline results for a long term treatment study evaluating DCCR (Diazoxide… [Read More]

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has received positive results in preclinical studies evaluating its lead therapeutic candidate, TTX-MC138, which was delivered to human glioblastoma multiforme… [Read More]

Exscientia plc (Nasdaq: EXAI) has entered a multi-year collaboration with Merck KGaA, Darmstadt, Germany focused on the discovery of novel small molecule drug candidates in… [Read More]

BioStem Technologies (OTC: BSEM) has inked an agreement with Venture Medical, a leading US wound market solutions provider, for the nationwide release of its innovative… [Read More]

Late-stage biopharmaceutical company, SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from its… [Read More]

  Cassava Sciences, Inc. (Nasdaq: SAVA) has announced a positive interim safety review of its lead candidate, simufilam currently under evaluation in patients with Alzheimer’s… [Read More]

Global gene therapy leader, Orchard Therapeutics (Nasdaq: ORTX), has submitted a Biologics License Application (BLA) for OTL-200 in metachromatic leukodystrophy (MLD) under Priority Review. The… [Read More]